This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Results

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Statins were clearly beneficial for patients with diabetes and for those high-risk non-diabetic patients enrolled in the study.

There were reductions in the event rate for first presentation of any major vascular events:

  • 22% reduction for treated diabetics (p<0.0001) vs. placebo-treated diabetics
  • there were similar reductions in the other high risk patients

Sub-group analysis demonstrated that:

  • diabetics who did not have overt vascular disease at entry into the trial had a highly significant 33% reduction in the event rate in simvastatin-treated vs. placebo-treated patients
  • diabetics with an LDL-cholesterol lower than 3.0 mmol/L (116 mg/dL) had a significant 27% reduction in the event rate in simvastatin-treated vs. placebo-treated patients
  • similar rate reductions were seen for diabetics with total cholesterol less than 5.0 mmol/L (193 mg/dL)

 

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.